Literature DB >> 24071522

Moving around the molecule: relationship between chemical structure and in vivo activity of synthetic cannabinoids.

Jenny L Wiley1, Julie A Marusich2, John W Huffman3.   

Abstract

Originally synthesized for research purposes, indole- and pyrrole-derived synthetic cannabinoids are the most common psychoactive compounds contained in abused products marketed as "spice" or "herbal incense." While CB1 and CB2 receptor affinities are available for most of these research chemicals, in vivo pharmacological data are sparse. In mice, cannabinoids produce a characteristic profile of dose-dependent effects: antinociception, hypothermia, catalepsy and suppression of locomotion. In combination with receptor binding data, this tetrad battery has been useful in evaluation of the relationship between the structural features of synthetic cannabinoids and their in vivo cannabimimetic activity. Here, published tetrad studies are reviewed and additional in vivo data on synthetic cannabinoids are presented. Overall, the best predictor of likely cannabimimetic effects in the tetrad tests was good CB1 receptor affinity. Further, retention of good CB1 affinity and in vivo activity was observed across a wide array of structural manipulations of substituents of the prototypic aminoalkylindole molecule WIN55,212-2, including substitution of an alkyl for the morpholino group, replacement of an indole core with a pyrrole or phenylpyrrole, substitution of a phenylacetyl or tetramethylcyclopropyl group for JWH-018's naphthoyl, and halogenation of the naphthoyl group. This flexibility of cannabinoid ligand-receptor interactions has been a particular challenge for forensic scientists who have struggled to identify and regulate each new compound as it has appeared on the drug market. One of the most pressing future research needs is determination of the extent to which the pharmacology of these synthetic cannabinoids may differ from those of classical cannabinoids.
© 2013.

Entities:  

Keywords:  Alkylindoles; Aromatic stacking; Cannabinoids; Herbal marijuana; Indoles; JWH-018; Pyrroles; Review; Spice; Synthetic cannabinoids

Mesh:

Substances:

Year:  2013        PMID: 24071522      PMCID: PMC3944940          DOI: 10.1016/j.lfs.2013.09.011

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  50 in total

1.  Cannabinoid agonist signal transduction in rat brain: comparison of cannabinoid agonists in receptor binding, G-protein activation, and adenylyl cyclase inhibition.

Authors:  C S Breivogel; S R Childers
Journal:  J Pharmacol Exp Ther       Date:  2000-10       Impact factor: 4.030

2.  Pharmacology of pravadoline: a new analgesic agent.

Authors:  D R Haubrich; S J Ward; E Baizman; M R Bell; J Bradford; R Ferrari; M Miller; M Perrone; A K Pierson; J K Saelens
Journal:  J Pharmacol Exp Ther       Date:  1990-11       Impact factor: 4.030

3.  Analysis of synthetic cannabinoids using high-resolution mass spectrometry and mass defect filtering: implications for nontargeted screening of designer drugs.

Authors:  Megan Grabenauer; Wojciech L Krol; Jenny L Wiley; Brian F Thomas
Journal:  Anal Chem       Date:  2012-06-20       Impact factor: 6.986

4.  Synthesis and pharmacology of 1-alkyl-3-(1-naphthoyl)indoles: steric and electronic effects of 4- and 8-halogenated naphthoyl substituents.

Authors:  Jenny L Wiley; Valerie J Smith; Jianhong Chen; Billy R Martin; John W Huffman
Journal:  Bioorg Med Chem       Date:  2012-01-30       Impact factor: 3.641

5.  Pharmacology and stereoselectivity of structurally novel cannabinoids in mice.

Authors:  P J Little; D R Compton; M R Johnson; L S Melvin; B R Martin
Journal:  J Pharmacol Exp Ther       Date:  1988-12       Impact factor: 4.030

6.  Structure-activity relationships for 1-alkyl-3-(1-naphthoyl)indoles at the cannabinoid CB(1) and CB(2) receptors: steric and electronic effects of naphthoyl substituents. New highly selective CB(2) receptor agonists.

Authors:  John W Huffman; Gulay Zengin; Ming-Jung Wu; Jianzhong Lu; George Hynd; Kristen Bushell; Alicia L S Thompson; Simon Bushell; Cindy Tartal; Dow P Hurst; Patricia H Reggio; Dana E Selley; Michael P Cassidy; Jenny L Wiley; Billy R Martin
Journal:  Bioorg Med Chem       Date:  2005-01-03       Impact factor: 3.641

7.  UR-144 in products sold via the Internet: identification of related compounds and characterization of pyrolysis products.

Authors:  Pierce Kavanagh; Andrej Grigoryev; Sergey Savchuk; Irina Mikhura; Andrew Formanovsky
Journal:  Drug Test Anal       Date:  2013-01-11       Impact factor: 3.345

8.  Cannabinoid structure-activity relationships: correlation of receptor binding and in vivo activities.

Authors:  D R Compton; K C Rice; B R De Costa; R K Razdan; L S Melvin; M R Johnson; B R Martin
Journal:  J Pharmacol Exp Ther       Date:  1993-04       Impact factor: 4.030

9.  Cannabinoid pharmacological properties common to other centrally acting drugs.

Authors:  Jenny L Wiley; Billy R Martin
Journal:  Eur J Pharmacol       Date:  2003-06-27       Impact factor: 4.432

10.  Use of SPME-HS-GC-MS for the analysis of herbal products containing synthetic cannabinoids.

Authors:  Anderson O Cox; Richard C Daw; Michele D Mason; Megan Grabenauer; Poonam G Pande; Kenneth H Davis; Jenny L Wiley; Peter R Stout; Brian F Thomas; John W Huffman
Journal:  J Anal Toxicol       Date:  2012-06       Impact factor: 3.367

View more
  42 in total

Review 1.  Minireview: From the bench, toward the clinic: therapeutic opportunities for cannabinoid receptor modulation.

Authors:  Robert P Picone; Debra A Kendall
Journal:  Mol Endocrinol       Date:  2015-04-13

Review 2.  Baths salts, spice, and related designer drugs: the science behind the headlines.

Authors:  Michael H Baumann; Ernesto Solis; Lucas R Watterson; Julie A Marusich; William E Fantegrossi; Jenny L Wiley
Journal:  J Neurosci       Date:  2014-11-12       Impact factor: 6.167

3.  In vitro determination of the efficacy of illicit synthetic cannabinoids at CB1 receptors.

Authors:  Shivani Sachdev; Kiran Vemuri; Samuel D Banister; Mitchell Longworth; Michael Kassiou; Marina Santiago; Alexandros Makriyannis; Mark Connor
Journal:  Br J Pharmacol       Date:  2019-12-10       Impact factor: 8.739

Review 4.  New approaches and challenges to targeting the endocannabinoid system.

Authors:  Vincenzo Di Marzo
Journal:  Nat Rev Drug Discov       Date:  2018-08-17       Impact factor: 84.694

5.  Evaluation of a homogenous enzyme immunoassay for the detection of synthetic cannabinoids in urine.

Authors:  Allan J Barnes; Sheena Young; Eliani Spinelli; Thomas M Martin; Kevin L Klette; Marilyn A Huestis
Journal:  Forensic Sci Int       Date:  2014-04-24       Impact factor: 2.395

Review 6.  Intracranial self-stimulation to evaluate abuse potential of drugs.

Authors:  S Stevens Negus; Laurence L Miller
Journal:  Pharmacol Rev       Date:  2014-07       Impact factor: 25.468

7.  Tolerance to hypothermic and antinoceptive effects of ∆9-tetrahydrocannabinol (THC) vapor inhalation in rats.

Authors:  Jacques D Nguyen; Yanabel Grant; Tony M Kerr; Arnold Gutierrez; Maury Cole; Michael A Taffe
Journal:  Pharmacol Biochem Behav       Date:  2018-07-19       Impact factor: 3.533

8.  Short-Term Genetic Selection for Adolescent Locomotor Sensitivity to Delta9-Tetrahydrocannabinol (THC).

Authors:  Chelsea R Kasten; Yanping Zhang; Ken Mackie; Stephen L Boehm
Journal:  Behav Genet       Date:  2018-03-17       Impact factor: 2.805

9.  Effect of the novel synthetic cannabinoids AKB48 and 5F-AKB48 on "tetrad", sensorimotor, neurological and neurochemical responses in mice. In vitro and in vivo pharmacological studies.

Authors:  Isabella Canazza; Andrea Ossato; Claudio Trapella; Anna Fantinati; Maria Antonietta De Luca; Giulia Margiani; Fabrizio Vincenzi; Claudia Rimondo; Fabiana Di Rosa; Adolfo Gregori; Katia Varani; Pier Andrea Borea; Giovanni Serpelloni; Matteo Marti
Journal:  Psychopharmacology (Berl)       Date:  2016-08-15       Impact factor: 4.530

Review 10.  Cannabinoids and Tremor Induced by Motor-related Disorders: Friend or Foe?

Authors:  Shokouh Arjmand; Zohreh Vaziri; Mina Behzadi; Hassan Abbassian; Gary J Stephens; Mohammad Shabani
Journal:  Neurotherapeutics       Date:  2015-10       Impact factor: 7.620

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.